Prognostic impact of COX-2 in non-small cell lung cancer: A comprehensive compartment-specific evaluation of tumor and stromal cell expression

Cancer Letters

Volumn 356, Issue 2, 2015, Pages 837-845

  Mattsson, Johanna S M ^a   Bergman, Bengt ^b   Grinberg, Marianna ^c   Edlund, Karolina ^c   Marincevic, Millaray ^a   Jirström, Karin ^d   Pontén, Fredrik ^a   Hengstler, Jan G ^c   Rahnenführer, Jörg ^c   Karlsson, Mats G ^e   Karlsson, Christina ^e   Helenius, Gisela ^e   Botling, Johan ^a   Micke, Patrick ^a   Gulyas, Miklos ^a  

^a UPPSALA UNIVERSITY   (Sweden)

^b SAHLGRENSKA UNIVERSITY HOSPITAL   (Sweden)

^c TU DORTMUND UNIVERSITY   (Germany)

^d LUND UNIVERSITY   (Sweden)

^e ÖREBRO UNIVERSITY HOSPITAL   (Sweden)

Author keywords

Cyclooxygenase 2; Immunohistochemistry; Lung cancer; Microarray; Prognosis; PTGS2

Indexed keywords

CYCLOOXYGENASE 2; MESSENGER RNA; PTGS2 PROTEIN, HUMAN; TUMOR MARKER;

AGED; ARTICLE; CANCER CLASSIFICATION; CANCER PROGNOSIS; CANCER STAGING; CONTROLLED STUDY; FEMALE; GENE; GENE EXPRESSION; GENETIC ANALYSIS; GENETIC ASSOCIATION; GENETIC TRANSCRIPTION; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; MALE; NON SMALL CELL LUNG CANCER; OVERALL SURVIVAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; PTGS2 GENE; STROMA CELL; ADENOCARCINOMA; COHORT ANALYSIS; ENZYME IMMUNOASSAY; GENETICS; IN SITU HYBRIDIZATION; LARGE CELL CARCINOMA; LUNG TUMOR; METABOLISM; MORTALITY; PATHOLOGY; REAL TIME POLYMERASE CHAIN REACTION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SQUAMOUS CELL CARCINOMA;

ADENOCARCINOMA; AGED; CARCINOMA, LARGE CELL; CARCINOMA, NON-SMALL-CELL LUNG; CARCINOMA, SQUAMOUS CELL; COHORT STUDIES; CYCLOOXYGENASE 2; FEMALE; HUMANS; IMMUNOENZYME TECHNIQUES; IN SITU HYBRIDIZATION; LUNG NEOPLASMS; MALE; REAL-TIME POLYMERASE CHAIN REACTION; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER; STROMAL CELLS; TUMOR MARKERS, BIOLOGICAL;

EID: 84919444431     PISSN: 03043835     EISSN: 18727980     Source Type: Journal    
DOI: 10.1016/j.canlet.2014.10.032     Document Type: Article

References (54)

1. Ghosal R., Kloer P., Lewis K.E. A review of novel biological tools used in screening for the early detection of lung cancer. Postgrad. Med. J. 2009, 85:358-363.
2. Lu J., Lee-Gabel L., Nadeau M.C., Ferencz T.M., Soefje S.A. Clinical evaluation of compounds targeting PD-1/PD-L1 pathway for cancer immunotherapy. J. Oncol. Pharm. Pract 2014, pii: 1078155214538087.
3. Borrello M.G., Degl'Innocenti D., Pierotti M.A. Inflammation and cancer: the oncogene-driven connection. Cancer Lett 2008, 267:262-270.
4. Shigdar S., Li Y., Bhattacharya S., O'Connor M., Pu C., Lin J., et al. Inflammation and cancer stem cells. Cancer Lett 2014, 345:271-278.
5. Mantovani A., Allavena P., Sica A., Balkwill F. Cancer-related inflammation. Nature 2008, 454:436-444.
6. Vandercappellen J., Van Damme J., Struyf S. The role of CXC chemokines and their receptors in cancer. Cancer Lett 2008, 267:226-244.
7. Zha S., Yegnasubramanian V., Nelson W.G., Isaacs W.B., De Marzo A.M. Cyclooxygenases in cancer: progress and perspective. Cancer Lett 2004, 215:1-20.
8. Maekawa M., Sugano K., Sano H., Miyazaki S., Ushiama M., Fujita S., et al. Increased expression of cyclooxygenase-2 to -1 in human colorectal cancers and adenomas, but not in hyperplastic polyps. Jpn. J. Clin. Oncol 1998, 28:421-426.
9. Chan G., Boyle J.O., Yang E.K., Zhang F., Sacks P.G., Shah J.P., et al. Cyclooxygenase-2 expression is up-regulated in squamous cell carcinoma of the head and neck. Cancer Res 1999, 59:991-994.
10. Shamma A., Yamamoto H., Doki Y., Okami J., Kondo M., Fujiwara Y., et al. Up-regulation of cyclooxygenase-2 in squamous carcinogenesis of the esophagus. Clin. Cancer Res 2000, 6:1229-1238.
11. Gupta S., Srivastava M., Ahmad N., Bostwick D.G., Mukhtar H. Over-expression of cyclooxygenase-2 in human prostate adenocarcinoma. Prostate 2000, 42:73-78.
12. Yuan A., Yu C.J., Shun C.T., Luh K.T., Kuo S.H., Lee Y.C., et al. Total cyclooxygenase-2 mRNA levels correlate with vascular endothelial growth factor mRNA levels, tumor angiogenesis and prognosis in non-small cell lung cancer patients. Int. J. Cancer 2005, 115:545-555.
13. Lu C., Soria J.C., Tang X., Xu X.C., Wang L., Mao L., et al. Prognostic factors in resected stage I non-small-cell lung cancer: a multivariate analysis of six molecular markers. J. Clin. Oncol 2004, 22:4575-4583.
14. Araki K., Hashimoto K., Ardyanto T.D., Osaki M., Shomori K., Nakamura H., et al. Co-expression of Cox-2 and EGFR in stage I human bronchial adenocarcinomas. Lung Cancer 2004, 45:161-169.
15. Kim H.S., Youm H.R., Lee J.S., Min K.W., Chung J.H., Park C.S. Correlation between cyclooxygenase-2 and tumor angiogenesis in non-small cell lung cancer. Lung Cancer 2003, 42:163-170.
16. Brabender J., Park J., Metzger R., Schneider P.M., Lord R.V., Hölscher A.H., et al. Prognostic significance of cyclooxygenase 2 mRNA expression in non-small cell lung cancer. Ann. Surg 2002, 235:440-443.
17. Van Dyke A.L., Cote M.L., Prysak G.M., Claeys G.B., Wenzlaff A.S., Murphy V.C., et al. COX-2/EGFR expression and survival among women with adenocarcinoma of the lung. Carcinogenesis 2008, 29:1781-1787.
18. Lim B.J., Jung S.S., Choi S.Y., Lee C.S. Expression of metastasis-associated molecules in non-small cell lung cancer and their prognostic significance. Mol. Med. Rep 2010, 3:43-49.
19. Kim S.J., Rabbani Z.N., Dong F., Vollmer R.T., Schreiber E.G., Dewhirst M.W., et al. Phosphorylated epidermal growth factor receptor and cyclooxygenase-2 expression in localized non-small cell lung cancer. Med. Oncol 2010, 27:91-97.
20. Tsubochi H., Sato N., Hiyama M., Kaimori M., Endo S., Sohara Y., et al. Combined analysis of cyclooxygenase-2 expression with p53 and Ki-67 in nonsmall cell lung cancer. Ann. Thorac. Surg 2006, 82:1198-1204.
21. Laga A.C., Zander D.S., Cagle P.T. Prognostic significance of cyclooxygenase 2 expression in 259 cases of non-small cell lung cancer. Arch. Pathol. Lab. Med 2005, 129:1113-1117.
22. Richardson C.M., Richardson D., Swinson D.E., Swain W.A., Cox G., O'Byrne K.J. Cyclooxygenase-2 protein levels are independent of epidermal growth factor receptor expression or activation in operable non-small cell lung cancer. Lung Cancer 2005, 48:47-57.
23. Khuri F.R., Wu H., Lee J.J., Kemp B.L., Lotan R., Lippman S.M., et al. Cyclooxygenase-2 overexpression is a marker of poor prognosis in stage I non-small cell lung cancer. Clin. Cancer Res 2001, 7:861-867.
24. Achiwa H., Yatabe Y., Hida T., Kuroishi T., Kozaki K., Nakamura S., et al. Prognostic significance of elevated cyclooxygenase 2 expression in primary, resected lung adenocarcinomas. Clin. Cancer Res 1999, 5:1001-1005.
25. Groen H.J., Sietsma H., Vincent A., Hochstenbag M.M., van Putten J.W., van den Berg A., et al. Randomized, placebo-controlled phase III study of docetaxel plus carboplatin with celecoxib and cyclooxygenase-2 expression as a biomarker for patients with advanced non-small-cell lung cancer: the NVALT-4 study. J. Clin. Oncol 2011, 29:4320-4326.
26. Micke P., Edlund K., Holmberg L., Kultima H.G., Mansouri L., Ekman S., et al. Gene copy number aberrations are associated with survival in histologic subgroups of non-small cell lung cancer. J. Thorac. Oncol 2011, 6:1833-1840.
27. Botling J., Edlund K., Lohr M., Hellwig B., Holmberg L., Lambe M., et al. Biomarker discovery in non-small cell lung cancer: integrating gene expression profiling, meta-analysis, and tissue microarray validation. Clin. Cancer Res 2013, 19:194-204.
28. Zhu C.Q., Ding K., Strumpf D., Weir B.A., Meyerson M., Pennell N., et al. Prognostic and predictive gene signature for adjuvant chemotherapy in resected non-small-cell lung cancer. J. Clin. Oncol 2010, 28:4417-4424.
29. Raponi M., Zhang Y., Yu J., Chen G., Lee G., Taylor J.M., et al. Gene expression signatures for predicting prognosis of squamous cell and adenocarcinomas of the lung. Cancer Res 2006, 66:7466-7472.
30. Bild A.H., Yao G., Chang J.T., Wang Q., Potti A., Chasse D., et al. Oncogenic pathway signatures in human cancers as a guide to targeted therapies. Nature 2006, 439:353-357.
31. Hou J., Aerts J., den Hamer B., van Ijcken W., den Bakker M., Riegman P., et al. Gene expression-based classification of non-small cell lung carcinomas and survival prediction. PLoS ONE 2010, 5:e10312.
32. Okayama H., Kohno T., Ishii Y., Shimada Y., Shiraishi K., Iwakawa R., et al. Identification of genes upregulated in ALK-positive and EGFR/KRAS/ALK-negative lung adenocarcinomas. Cancer Res 2012, 72:100-111.
33. Xie Y., Xiao G., Coombes K.R., Behrens C., Solis L.M., Raso G., et al. Robust gene expression signature from formalin-fixed paraffin-embedded samples predicts prognosis of non-small-cell lung cancer patients. Clin. Cancer Res 2011, 17:5705-5714.
34. Shedden K., Taylor J.M., Enkemann S.A., Tsao M.S., Yeatman T.J., Gerald W.L., et al. Gene expression-based survival prediction in lung adenocarcinoma: a multi-site, blinded validation study. Nat. Med 2008, 14:822-827.
35. Lohr M., Edlund K., Botling J., Hammad S., Hellwig B., Othman A., et al. The prognostic relevance of tumour-infiltrating plasma cells and immunoglobulin kappa C indicates an important role of the humoral immune response in non-small cell lung cancer. Cancer Lett 2013, 333:222-228.
36. Karlsson C., Helenius G., Fernandes O., Karlsson M.G. Oestrogen receptor β in NSCLC-prevalence, proliferative influence, prognostic impact and smoking. APMIS 2012, 120:451-458.
37. Holm S. A simple sequentially rejective multiple test procedure. Scand. J. Stat 1979, 6:65-70.
38. Zhan P., Qian Q., Yu L.K. Prognostic value of COX-2 expression in patients with non-small cell lung cancer: a systematic review and meta-analysis. J. Thorac. Dis 2013, 5:40-47.
39. Jiang H., Wang J., Zhao W. Cox-2 in non-small cell lung cancer: a meta-analysis. Clin. Chim. Acta 2013, 419:26-32.
40. O'Hurley G., Sjöstedt E., Rahman A., Li B., Kampf C., Pontén F., et al. Garbage in, garbage out: a critical evaluation of strategies used for validation of immunohistochemical biomarkers. Mol. Oncol 2014, 8:783-798.
41. Lindskog C., Edlund K., Mattsson J., Micke P. The quest for novel tissue-based prognostic biomarkers in non-small cell lung cancer. Exp. Opin. Mol. Diagn 2014, in press.
42. Sangaletti S., Colombo M.P. Matricellular proteins at the crossroad of inflammation and cancer. Cancer Lett 2008, 267:245-253.
43. Paulsson J., Micke P. Prognostic relevance of cancer-associated fibroblasts in human cancer. Semin. Cancer Biol 2014, 25:61-68.
44. Bremnes R.M., Al-Shibli K., Donnem T., Sirera R., Al-Saad S., Andersen S., et al. The role of tumor-infiltrating immune cells and chronic inflammation at the tumor site on cancer development, progression, and prognosis: emphasis on non-small cell lung cancer. J. Thorac. Oncol 2011, 6:824-833.
45. Lievense L.A., Bezemer K., Aerts J.G., Hegmans J.P. Tumor-associated macrophages in thoracic malignancies. Lung Cancer 2013, 80:256-262.
46. Schmidt M., Hellwig B., Hammad S., Othman A., Lohr M., Chen Z., et al. A comprehensive analysis of human gene expression profiles identifies stromal immunoglobulin κ C as a compatible prognostic marker in human solid tumors. Clin. Cancer Res 2012, 18:2695-2703.
47. Giardiello F.M., Hamilton S.R., Krush A.J., Piantadosi S., Hylind L.M., Celano P., et al. Treatment of colonic and rectal adenomas with sulindac in familial adenomatous polyposis. N. Engl. J. Med 1993, 328:1313-1316.
48. Eli Y., Przedecki F., Levin G., Kariv N., Raz A. Comparative effects of indomethacin on cell proliferation and cell cycle progression in tumor cells grown in vitro and in vivo. Biochem. Pharmacol 2001, 61:565-571.
49. Tomozawa S., Nagawa H., Tsuno N., Hatano K., Osada T., Kitayama J., et al. Inhibition of haematogenous metastasis of colon cancer in mice by a selective COX-2 inhibitor, JTE-522. Br. J. Cancer 1999, 81:1274-1279.
50. Sahin I.H., Hassan M.M., Garrett C.R. Impact of non-steroidal anti-inflammatory drugs on gastrointestinal cancers: current state-of-the science. Cancer Lett 2014, 345:249-257.
51. Edelman M.J., Watson D., Wang X., Morrison C., Kratzke R.A., Jewell S., et al. Eicosanoid modulation in advanced lung cancer: cyclooxygenase-2 expression is a positive predictive factor for celecoxib+chemotherapy - cancer and Leukemia Group B Trial 30203. J. Clin. Oncol 2008, 26:848-855.
52. Koch A., Bergman B., Holmberg E., Sederholm C., Ek L., Kosieradzki J., et al. Effect of celecoxib on survival in patients with advanced non-small cell lung cancer: a double blind randomised clinical phase III trial (CYCLUS study) by the Swedish Lung Cancer Study Group. Eur. J. Cancer 2011, 47:1546-1555.
53. Gridelli C., Gallo C., Ceribelli A., Gebbia V., Gamucci T., Ciardiello F., et al. Factorial phase III randomised trial of rofecoxib and prolonged constant infusion of gemcitabine in advanced non-small-cell lung cancer: the GEmcitabine-COxib in NSCLC (GECO) study. Lancet Oncol 2007, 8:500-512.
54. Gitlitz B.J., Bernstein E., Santos E.S., Otterson G.A., Milne G., Syto M., et al. A randomized, placebo-controlled, multicenter, biomarker-selected, phase 2 study of apricoxib in combination with erlotinib in patients with advanced non-small-cell lung cancer. J. Thorac. Oncol 2014, 9:577-582.